Background. We report the first nationally representative prevalence data on genital human papillomavirus (HPV) in males in the United States, using findings from the National Health and Nutrition Examination Surveys, 2013-2014.
Human papillomavirus (HPV) infection is the most prevalent sexually transmitted infection in men and women worldwide [1] [2] [3] ; >150 HPV types have been identified [4, 5] . While most infections are asymptomatic and transient, high-risk HPV (HR-HPV) types, when persistent, can cause cervical, vulvar, and vaginal cancers in women; penile cancers in men; and anal, oropharyngeal, and other cancers in both women and men [6, 7] . Other HPV types (particularly 6 and 11) can cause genital warts [6] .
In the United States, the Advisory Committee on Immunization Practices (ACIP) has recommended routine HPV vaccination at age 11 or 12 years for girls since 2006 and for boys since 2011 [8, 9] . The ACIP also recommends vaccination through age 26 years for females, through age 21 years for males, and through age 26 years for men who have sex with men (MSM), if not previously vaccinated [8] . Through 2014, almost all HPV vaccine used in the United States was the quadrivalent vaccine (4vHPV), which targets HPV types 6, 11, 16, and 18 . Measuring the prevalence of genital HPV infections is an important component of monitoring the population-level impact of the vaccination program. The prevalence of HPV infections in females has been monitored in self-collection of cervicovaginal swabs by participants in the National Health and Nutrition Examination Surveys (NHANES), a series of cross-sectional surveys and health examinations, since 2003 [10] [11] [12] [13] . In 2013-2014, for the first time, NHANES also included an assessment of HPV prevalence in males, using self-collected genital swabs.
Studies from the United Kingdom and Denmark have reported the prevalence of anogenital HPV in males participating in nationally representative studies [14, 15] . However, in the United States, most studies of HPV in men have been clinic based, conducted in other special communities (eg, university students and MSM), or conducted in cohorts recruited for studies on the natural history of HPV [16] [17] [18] [19] [20] . The purpose of this study is to provide the first national estimate of genital HPV DNA prevalence in males aged 14-59 years, to describe the epidemiology of genital HPV infections in the US male population, and to explore evidence of HPV vaccine impact.
METHODS

Survey Design and Population
The National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC) administers NHANES. Each 2-year NHANES cycle is designed to be representative of the civilian, noninstitutionalized US population. Complex, multistage probability sampling is used to select participants [21] . In 2013-2014, groups oversampled to increase reliability and precision of subgroup estimates included persons who were Hispanic, non-Hispanic black, non-Hispanic Asian, non-Hispanic white, and others (non-Hispanic and races other than black, Asian, or white) whose household incomes were ≤130% of the federal poverty level, as well as non-Hispanic white and other persons who were ≥80 years old [21] . Consenting participants were interviewed in their homes and underwent a physical examination and an audio computer-assisted self-interview (audio-CASI) in a mobile examination center (MEC) [22] . The response rate to 2013-2014 NHANES among males was 70.6% for the questionnaire portion and 68.1% for the examination portion. Among 2326 males aged 14-59 years who were examined in the MEC, 2177 (93.6%) submitted a specimen, and 2046 (88.0%) had adequate HPV DNA typing results (see the "Laboratory Methods" subsection below). The study was approved by the CDC/NCHS Research Ethics Review Board.
Demographic, Behavioral, and Vaccination Data
Information on age, race, education, income, marital status, vaccination history, and country of birth was ascertained during household interviews; a proxy responded for participants aged <16 years [23] . Information on sexual history was ascertained for participants aged 14-59 years, using an audio-CASI [22] . For respondents who reported ever having sex, defined as vaginal, oral, or anal sex, additional questions were asked regarding sex partners. The question about circumcision status was asked with a visual aid [24] .
Specimen Collection and Processing
MEC personnel explained the process for self-collecting external genital samples to participants and provided illustrated instructions. Participants were given an individually packaged sterile polyester swab (Puritan Medical, Guilford, MA) and specimen collection vial with 1 mL of specimen transport medium (STM; Qiagen, Valencia, CA). Participants were instructed to wash hands and to avoid touching the end of the swab or the swab shaft near the swab. They were instructed to rub all surfaces of the penis with the swab; uncircumcised participants were instructed to pull back the foreskin. After collection, participants placed the swab in the vial and returned the vial to study personnel. Vials were stored at 4°C and shipped to CDC on dry ice within 2 weeks. At the CDC, the sample in specimen transport medium was maintained at 4°C until extraction within 4 weeks.
Laboratory Methods
DNA extractions were performed using the automated Chemagic MSM1 extractor and Chemagic Viral NA/gDNA kit (Perkin Elmer, Waltham, MA) [25] . The extract (total volume, 100 μL) was tested immediately or stored at −20°C. For every 40 samples, a water blank was processed through all steps of extraction, to serve as a contamination control.
HPV detection and typing were performed on all specimens, using the research-use-only Linear Array assay (Roche Diagnostics) [25] . This assay uses an HPV L1 consensus polymerase chain reaction (PCR) with biotinylated PGMY0911 primer sets and β-globin as an internal control for sample amplification and detects 37 HPV types (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 
Data Analysis
Data management and analysis were performed using SAScallable SUDAAN 11.0 (RTI International, Research Triangle Park, NC). Examination sampling weights were used to generate nationally representative estimates [27] . Estimates with relative standard errors (RSEs) of > 30% were considered unstable.
The income-to-poverty ratio was calculated on the basis of self-reported income, family size, and state-specific poverty guidelines for 2013-2014 (a ratio of <1 classifies income as below the poverty level). HPV categories considered included any HPV (any of the 37 types detected by the Linear Array assay), any of 14 HR-HPV types detected by clinical HPV tests (16, 18, 31, 33, 35, 39, 45 , 51, 52, 56, 58, 59, 66, or 68), 4vHPV types (6, 11, 16, or 18) , 4vHPV HR types (16 or 18) , all non4vHPV types (the other 33 types), non-4vHPV HR types (all HR-HPV types except 16 and 18) , and additional HPV types in the 9-valent HPV vaccine (9vHPV; 31, 33, 45, 52, or 58).
We estimated the prevalence of any HPV and HR-HPV overall and by demographic and behavioral characteristics and tested for statistically significant differences, using Wald χ 2 tests. We estimated the prevalence of 4vHPV, 4vHPV HR, non4vHPV, non-4vHPV HR, and non-4vHPV types and additional 9vHPV types by age group (14-19, 20-24, 25-29, 30-39, 40-49 , and 50-59 years).
Selected analyses were performed among sexually active males to better understand the influences of sexual behavior on genital HPV prevalence across age groups. First, we examined the distribution of sexual behaviors by age group. Next, we developed multivariable models to evaluate the influence of the number of sex partners and other sexual behaviors on prevalence of any HPV and HR-HPV. Both models included lifetime and past-year number of sex partners, age group, and race/ethnicity. The other variables considered for adjustment were sex with a same-sex partner, age at first sex, circumcision status, country of birth, and poverty level. These were selected using backward elimination (F test P < .1 to stay); we also considered change-in-estimate criteria (≥10% change in PR for age group, lifetime number of sex partners, or past-year number of sex partners), but no additional variables met these criteria. We present unadjusted PRs and adjusted PRs (aPRs) and 95% confidence intervals (CIs).
To explore evidence of HPV vaccine impact, we compared age-specific vaccine type and nonvaccine type HPV prevalence. We hypothesized that the age distribution of vaccine types and nonvaccine types might differ, as the vaccination program would be expected to reduce acquisition of vaccine type but not nonvaccine type infections in younger age groups. To test this, we compared prevalence of 4vHPV and non-4vHPV types in consecutive age groups (eg, 20-24 vs 14-19 years and 25-29 vs 20-24 years). We also estimated the proportion of males and females who self-reported receiving ≥1 dose of HPV vaccine, stratified by age group, and determined age-specific 4vHPV type prevalence, stratified by vaccination history, in sexually active males aged 14-19 and 20-24 years.
RESULTS
Genital HPV Prevalence
Overall estimated prevalence of any genital HPV was 42.2% (95% CI, 38.3%-46.1%) among males aged 14-59 years (Table  1) . By age group, the prevalence of any HPV was 12.5% among males aged 14-19 years, 38.2% among males aged 20-24 years, 48.5% among males aged 25-29 years, and similar (range, 45.7-51.0%) in the 3 older age groups (Table 1) . By race/ethnicity, the prevalence of any HPV was highest in non-Hispanic blacks (59.4%) and lowest in Asians (23.7%). The prevalence of any HPV was not significantly different when stratified by poverty level or country of birth and was higher among circumcised males (44.0%) than among uncircumcised males (40.0%). The prevalence was higher among individuals with a greater lifetime number of sex partners, a greater past-year number of sex partners, and an earlier age at first sex, but it did not differ significantly according to having a same-sex partner.
Overall, the prevalence of HR-HPV was 23.4% (95% CI, 21.3%-25.6%); associations with demographic and behavioral characteristics were similar to those for any HPV, except that HR-HPV was significantly associated with poverty and country of birth (Table 1) .
The prevalence of individual HPV types was <7% for all types (Figure 1) . The most-prevalent types overall were non-HR-HPV types 62 (6.9%) and 84 (6.4%). Among HR-HPV types, the most prevalent were 51 (5.1%), 16 (4.0%), and 66 (3.9%).
Sexual Behavior and HPV Prevalence
We examined the relationship between lifetime and past-year number of sex partners and genital HPV prevalence among 1611 males who reported ever having sex. Among males aged 14-19 years, more than half reported having 1-2 lifetime sex partners, and about 10% reported having ≥15; in all age groups >30 years, over one third reported having ≥15 lifetime sex partners ( Figure 2A ). However, having multiple sex partners in the past year was most common in the 2 youngest age groups ( Figure 2B ). While the prevalences of any HPV and HR-HPV were similar in age groups of >25 years ( Figure 2C ), the percentage of men who reported having multiple past-year sex partners was lower among older men.
In unadjusted analyses, the prevalence of any HPV was significantly higher among males with a greater lifetime numbers of sex partners, multiple partners in the past year, and age ≥20 years ( Table 2 ). In the final model that included lifetime and past-year number of sex partners, age group, and race, aPR remained higher with greater lifetime numbers of sex partners; males with ≥15 lifetime sex partners had 3 times the prevalence of any HPV than males who had 1-2 lifetime sex partners (aPR, 3.27; 95% CI, 2.12-5.02). While men having ≥2 past-year sex partners had a significantly higher prevalence of any HPV than males who had no past-year sex partners, the magnitude of this association (aPR, 1.26) was lower than the association with lifetime number of sex partners. Males in all age groups of ≥20 years had a significantly higher prevalence than males aged 14-19 years (aPR range, 1.39-1.66), and non-Hispanic blacks had a higher prevalence than non-Hispanic whites (aPR, 1.24).
For HR-HPV, aPRs were higher with greater lifetime number of sex partners. The magnitude of this increase was larger than the association with any HPV: males with ≥15 lifetime sex partners had nearly 5 times the HR-HPV prevalence as males with 1-2 lifetime sex partners.
Evaluation of Vaccine Impact
Among males aged 14-59 years, the estimated prevalence of 4vHPV types was 7.9% (Table 3 ). The prevalence of 4vHPV types varied by age but did not follow the same pattern as that of non-4vHPV types. This is shown graphically, where the prevalences of 4vHPV types and non-4vHPV types, stratified by age, were not parallel in the 3 youngest age groups ( Figure 3A ). 4vHPV type prevalence was lowest among males aged 14-19 years (1.8%) and those aged 20-24 years (4.0%). The prevalence in males aged 25-29 years was 11.2%, significantly higher than in males aged 20-24 years (PR, 2.79; 95% CI, 1.31-5.96; Table 3 and Figure 3A ). The prevalence of 4vHPV types ranged from 9.1% to 9.6% in the 3 older age groups, and no other comparisons between consecutive age groups were statistically significant. The prevalence of 4vHPV HR types followed a similar pattern, with the largest difference between groups aged 20-24 years and 25-29 years. By contrast, the largest difference in prevalence of non-4vHPV types was between ages 14-19 years and 20-24 years (11.3% and 38.2%, respectively; PR, 3.39; 95% CI, 2.49-4.61); no other consecutive age group comparisons were statistically significant. The subset of non-4vHPV HR types and the 5 additional 9vHPV types followed a similar pattern of prevalence with respect to age as that of non-4vHPV types.
To explore reasons for the observed age differences in the prevalence of 4vHPV and non-4vHPV types, we examined the HPV vaccination history among males and females who participated in 2013-2014 NHANES. A history of ≥1 vaccine dose was 28% and 14.2% among males aged 14-19 years and 20-24 years, respectively. The proportion of individuals who were vaccinated was higher among females than among males in all age groups, and the percentage of vaccinated individuals decreased with increasing age among both males and females ( Figure 3B ). Among sexually active males aged 20-24 years, the prevalence of 4vHPV types was 4.2% (RSE, >30%) in vaccinated males and 4.6% (RSE, >30%) in unvaccinated males. Among sexually active males aged 14-19 years, no 4vHPV types were detected in vaccinated males, and the prevalence in unvaccinated males was 4.6% (RSE, >30%).
DISCUSSION
In this first nationally representative study of the genital HPV prevalence in adolescent and adult US males, in all age groups of >25 years nearly half of males had any HPV detected and about 1 in 4 had HR-HPV. These data are from the first cycle of NHANES (2013-2014), in which the prevalence of genital HPV DNA was determined in males. Since the recommendation for routine HPV vaccination of males was made in 2011 (females in 2006), data from this report cannot be regarded as a prevaccine baseline. Our analysis of age-specific prevalence of 4vHPV types and non-4vHPV types suggests that vaccination might already have impacted the prevalence in males. We found that the overall genital HPV prevalence in US males during 2013-2014 (42.2%) was similar to the cervicovaginal prevalence reported in US females in the prevaccine era (42.5%) [11] . However, age-specific prevalence differed from what has been observed in females. Prior reports using NHANES data [11] [12] [13] 28] , other data sources [29] , and data from many other countries [3] have shown that peak HPV prevalence in females occurs in young adulthood; at older ages, women have gradually lower prevalence. By contrast, we found that the prevalences of any HPV and HR-HPV reached high levels in young adult males and were similarly high in older age groups through 59 years. This age-associated pattern of prevalence in males is consistent with findings from a review of prevalence studies worldwide, which found that the HPV prevalence in males did not decline with age [2] , and with findings from incidence studies in the United States [16, 19] , although at least 1 nationally representative study (in Denmark) observed a lower prevalence in older men [14] . Possible mechanisms that would be consistent with a different age-associated pattern in males as compared to females include more acquisition of new infections due to having more new sex partners throughout the life course [20] , less naturally acquired immunity [30] , or perhaps a long persistence of a subset of infections acquired in young males, even though cervical infections have a longer average persistence than noncervical infections [31] . Of note, we found that the HPV prevalence in men in their 40s and 50s was similar to that in younger men, even though the proportion of older men who had multiple past-year sex partners was lower, also suggesting that a smaller proportion of older men than younger men had recently had new sex partners. The importance of total lifetime partners was also evident in the models, where we found that the most strongly associated determinant of higher HPV prevalence at all ages was the lifetime number of sex partners.
This study offers a snapshot of the epidemiology of genital HPV in US males. Of note, because Asians were oversampled in NHANES in 2013-2014, this study provides the first nationally representative estimates of genital HPV in Asians. We found that the prevalences of both HPV and HR-HPV were lowest in Asians and highest in non-Hispanic blacks as compared to other racial/ethnic groups. However, racial/ethnic differences were attenuated after adjustment for numbers of sex partners and demographic characteristics, and the only significant race difference in the final models was the higher prevalence of any HPV in non-Hispanic blacks as compared to whites. A 3-country study previously found that male genital HPV prevalence differed by race, with significantly lower prevalence in Asians than in whites [32] . Crude HPV prevalence was higher in circumcised than uncircumcised men, but in the adjusted models we found no association between HPV prevalence and circumcision, likely reflecting that circumcision status is associated with many other determinants of HPV acquisition in the diverse US population. Randomized controlled trials have found that circumcision is protective against HPV acquisition or that circumcised men clear infections more quickly [33] [34] [35] . However, the association of circumcision with HPV prevalence in observational, cross-sectional studies has been inconsistent and might depend on the anatomic site sampled [36] [37] [38] [39] [40] . Also, prevalence was not significantly higher in men who reported sex with a same-sex partner than in men who reported sex only with women, but the sample size of MSM was small. Other studies focusing on MSM have documented a high burden of HPV-related disease, particularly a high prevalence of anal HPV, which was not assessed in this study, but not necessarily a high prevalence of genital HPV [18, [41] [42] [43] .
In the absence of any vaccine impact, we would expect to see vaccine types and nonvaccine types follow the same general pattern with age as was seen in prevaccine-era NHANES data in females, namely a markedly higher HPV prevalence among participants aged 20-24 years than among participants aged 14-19 years, coinciding with the average age when sexual activity increases [13] ; however, among males in 2013-2014, we only observed this pattern for non-4vHPV types, not for 4vHPV types. We focused our analysis on differences in prevalence of vaccine types and nonvaccine types between age groups, rather than differences in vaccine and nonvaccine type prevalence within age groups, because the relative difference between the prevalence of 4vHPV and non-4vHPV types is large regardless of age group. Our findings could be consistent with a direct impact of male vaccination or indirect (herd) effects of female vaccination. Just over one quarter of males in the 14-19-year age group and only 14% in the 20-24-year age group reported that they had received ≥1 dose of HPV vaccine. Although the sample size from 2 years of NHANES was insufficient to yield stable estimates, we detected no 4vHPV type infections in sexually active vaccinated males in the 14-19-year age group. Among males aged 20-24 years, vaccine-type prevalence was also low in both unvaccinated and vaccinated males. Because vaccine coverage is higher among women and vaccine impact has been demonstrated in young women aged 14-19 and 20-24 years by use of NHANES 2009-2012 data [13] , an indirect effect on males due to decreased transmission from females could be largely responsible for the observed low prevalence of 4vHPV types in young males; direct impact of male vaccination could also be contributing to the low 4vHPV prevalence in 14-19 year olds. This interpretation is plausible because dramatic decreases in anogenital warts and vaccine-type prevalence in males have been documented following female-only vaccination programs in several countries [44] [45] [46] [47] . Findings from this study should be interpreted in light of several limitations. First, this analysis includes data from one 2-year cycle of NHANES, which can lead to unstable estimates. Second, differences by age group could result from cohort effects [29] , and firm conclusions cannot be drawn about incidence or changes in prevalence over the life course, based on cross-sectional data. Third, information on behaviors and vaccination are self-reported in NHANES; some degree of misreporting or incomplete recall is possible. Importantly, information on vaccination status was not verified by medical record review. The >1-dose vaccine uptake in males aged 14-19 years reported here is lower than the uptake frequencies of 33.6% and 41.9% in 2013 and 2014, respectively, estimated for 13-17-year-old males in a national survey, which does verify vaccination history [48] . Finally, the multivariable models were developed to investigate the influence of lifetime and recent numbers of sex partners on genital HPV prevalence; the prevalence ratios shown for other variables (ie, race, age, and poverty level) should be interpreted in this context and not as independent causal effects.
These nationally representative prevalence data show that the overall prevalence of genital HPV in US males is similar to the prevalence found in previous national surveys of cervicovaginal HPV infections in females. However, there are some differences in age-specific patterns. Our data may indicate evidence of vaccine impact in young US males aged 14-19 and 20-24 years in 2013-2014, likely attributable primarily to an indirect effect of vaccination of females. Future analyses comparing genital HPV prevalence between males and females during the same years and ongoing monitoring of HPV prevalence in the US population will be important for continuing to evaluate the impact of HPV vaccination in the United States. 
